EBITDA for Boston Scientific (BSX)
According to Boston Scientific's latest reported financial statements, the company's current EBITDA (TTM) is $4.76B USD. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a common proxy for operating cash generation that strips out non-cash charges (depreciation and amortization) and capital structure effects (interest, taxes). Useful for comparing companies with different leverage and asset bases — see operating income and net income for fully GAAP figures.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
Currently viewingEBITDASwitch metric
TTM (last 4 quarters)
$4.76B
YoY change
-5.2%
5Y CAGR
+19.8%
Peak year (2024)
$3.94B
Cumulative EBITDA
$33.43B
EBITDA history chart for Boston Scientific (BSX) from 1991 to 2025
EBITDA history table for Boston Scientific (BSX) from 1991 to 2025
| Fiscal year | Period ended | Reported | EBITDA | YoY |
|---|---|---|---|---|
| 2025 | $3.73B | -5.2% | ||
| 2024 | $3.94B | +14.0% | ||
| 2023 | $3.45B | +26.0% | ||
| 2022 | $2.74B | +8.9% | ||
| 2021 | $2.52B | +66.6% | ||
| 2020 | $1.51B | -31.6% | ||
| 2019 | $2.21B | -14.5% | ||
| 2018 | $2.58B | +28.8% | ||
| 2017 | $2.01B | +63.7% | ||
| 2016 | $1.23B | +240.6% | ||
| 2015 | $360.00M | -16.9% | ||
| 2014 | $433.00M | -39.9% | ||
| 2013 | $721.00M | -122.8% | ||
| 2012 | -$3.16B | -293.3% | ||
| 2011 | $1.64B | +997.3% | ||
| 2010 | $149.00M | -238.0% | ||
| 2009 | -$108.00M | -84.5% | ||
| 2008 | -$699.00M | -174.4% | ||
| 2007 | $940.00M | -140.5% | ||
| 2006 | -$2.32B | -279.1% | ||
| 2005 | $1.29B | -29.4% | ||
| 2004 | $1.83B | +97.1% | ||
| 2003 | $930.00M | +8.6% | ||
| 2002 | $856.00M | +39.4% | ||
| 2001 | $614.00M | -28.3% | ||
| 2000 | $856.00M | -5.2% | ||
| 1999 | $903.00M | +45.6% | ||
| 1998 | $620.00M | +21.8% | ||
| 1997 | $509.00M | +23.6% | ||
| 1996 | $411.80M | +37.3% | ||
| 1995 | $299.90M | +115.8% | ||
| 1994 | $139.00M | +20.9% | ||
| 1993 | $115.00M | +18.1% | ||
| 1992 | $97.40M | +31.8% | ||
| 1991 | $73.90M | — |
EBITDA values are taken from Boston Scientific's reported income statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
Boston Scientific (BSX) most recent annual EBITDA stands at $3.73B (2025) – declined 5.2% year-over-year.
Over 2020–2025 (5 years), Boston Scientific EBITDA expanded at a +19.8% compound annual rate, with the latest reading among the more recent periods of the dataset.
Between 2024 and 2025, Boston Scientific EBITDA declined 5.2%, falling from $3.94B to $3.73B.
Across the available history, EBITDA reached its high of $3.94B in 2024 and its low of -$3.16B in 2012.
Among 8 Healthcare peers, Boston Scientific (BSX) ranks 9th; the peer median for EBITDA is $24.21B.
Boston Scientific EBITDA by Year
Boston Scientific EBITDA 2025: $3.73B
Boston Scientific EBITDA in 2025 was $3.73B, declined 5.2% below 2024.
Boston Scientific EBITDA 2024: $3.94B
Boston Scientific EBITDA in 2024 was $3.94B, grew 14.0% from 2023. This figure represents the highest annual value in the available history.
Boston Scientific EBITDA 2023: $3.45B
Boston Scientific EBITDA in 2023 was $3.45B, grew 26.0% from 2022.
Boston Scientific EBITDA 2022: $2.74B
Boston Scientific EBITDA in 2022 was $2.74B, grew 8.9% from 2021.
Boston Scientific EBITDA 2021: $2.52B
Boston Scientific EBITDA in 2021 was $2.52B.
See more financial history for Boston Scientific (BSX).
Sector peers — EBITDA
Companies in the same sector as Boston Scientific, ranked by their latest EBITDA.
| Company | EBITDA | Sector |
|---|---|---|
| Novo Nordisk A/S (NVO) | $156.73B | Healthcare |
| Johnson & Johnson (JNJ) | $41.05B | Healthcare |
| Eli Lilly and Company (LLY) | $27.94B | Healthcare |
| Merck & Co., Inc. (MRK) | $25.36B | Healthcare |
| UnitedHealth Group Incorporated (UNH) | $23.06B | Healthcare |
| AstraZeneca PLC (AZN) | $19.83B | Healthcare |
| AbbVie Inc. (ABBV) | $17.63B | Healthcare |
| Amgen Inc. (AMGN) | $15.84B | Healthcare |
Frequently asked questions
What is Boston Scientific's EBITDA?
- Latest reported EBITDA for Boston Scientific (BSX) is $4.76B (period ending March 31, 2026).
How has Boston Scientific EBITDA changed year-over-year?
- Boston Scientific (BSX) EBITDA changed -5.2% year-over-year on the latest annual filing.
What is the long-term growth rate of Boston Scientific EBITDA?
- Boston Scientific (BSX) EBITDA compound annual growth rate is +19.8% over the most recent 5 years available.
When did Boston Scientific EBITDA hit its highest annual value?
- Boston Scientific EBITDA reached its highest annual value of $3.94B in 2024.
What was Boston Scientific EBITDA in 2024?
- Boston Scientific (BSX) EBITDA in 2024 was $3.94B.
What was Boston Scientific EBITDA in 2025?
- Boston Scientific (BSX) EBITDA in 2025 was $3.73B.
Metrics overview
Pick a metric for charts, filings, and peers — each row shows the latest TTM or annual value with year-over-year change.
Explore more
BSX Overview
Company profile, financial tools, and key metrics
BSX Revenue Counter
Earns $653.70 every second. See per minute, hour, and day.
BSX Earnings Counter
Earns $112.66 per second net profit. See per minute, hour, and day.
BSX Economic Scale
Exceeds Niger's GDP. Compare with world economies.
BSX What If Invested
What if you had invested $1,000? See historical returns from any date.
BSX How It Makes Money
Discover visual breakdown of $20.61B in revenue — where it comes from and where it goes.
BSX Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
BSX Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
BSX Daily Price Character
Balanced · 48.8% historical win rate (green days). Streaks & record days.
BSX Buybacks
Recent repurchase activity. Shareholder yield & SBC comparison.
BSX Stock Split History
2 splits on record. Dates, ratios, and cumulative multiple.